The Phase II clinical trial of SHJ002 ophthalmic solution for the treatment of corneal erosion in patients with Sjogren’s syndrome has completed treatment and full efficacy assessment for the last enrolled patient as of April 10, 2025.
We expect to complete unblinding and obtain preliminary statistical analysis results within the next two months.
